Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Current Assets (2023 - 2025)

Mangoceuticals' Current Assets history spans 3 years, with the latest figure at $598223.0 for Q3 2025.

  • For Q3 2025, Current Assets rose 474.84% year-over-year to $598223.0; the TTM value through Sep 2025 reached $598223.0, up 474.84%, while the annual FY2024 figure was $75595.0, 90.95% down from the prior year.
  • Current Assets for Q3 2025 was $598223.0 at Mangoceuticals, up from $117961.0 in the prior quarter.
  • Across five years, Current Assets topped out at $3.8 million in Q1 2023 and bottomed at $75595.0 in Q4 2024.
  • The 3-year median for Current Assets is $517561.0 (2024), against an average of $973110.8.
  • The largest annual shift saw Current Assets crashed 97.65% in 2024 before it soared 474.84% in 2025.
  • A 3-year view of Current Assets shows it stood at $835402.0 in 2023, then tumbled by 90.95% to $75595.0 in 2024, then soared by 691.35% to $598223.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Current Assets are $598223.0 (Q3 2025), $117961.0 (Q2 2025), and $176652.0 (Q1 2025).